Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin for COPD Inflammation
NCT02557958Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Jan 2009
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Azithromycin with Placebo (2 arms). Primary endpoint: Inflammatory markers at 2 months. Started Jan 2009; status: completed.
02
Drugs
azithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02557958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557958.